Whitehawk Therapeutics awarded Bryan Ball 183,266 derivative securities through two transactions at $0 per share. The transactions dated 2026-09-15 left him with 91,633 derivative securities, giving investors the stated award size, transaction price and resulting reported holding in one insider transaction record for the company.
Key Highlights
- The transactions were dated 15 September 2026.
- The derivative securities were awarded at $0 per share.
- Bryan Ball’s reported holding after the transactions was 91,633 derivative securities.
Whitehawk Therapeutics, Inc. (NASDAQ: WHWK) awarded Bryan Ball 183,266 derivative securities across two transactions. The transactions listed a per-share award price of $0.
Two Derivative Awards Recorded on 15 September 2026
The transactions were recorded on 15 September 2026 under code A, which identifies an award or grant. The record lists BALL BRYAN with the remark “See remarks.” Following the transactions, his reported ownership was 91,633 derivative securities. The award and resulting holding are separate figures in the transaction record. The first measures the securities covered by the two transactions, while the second identifies the derivative securities reported as owned afterward. Whitehawk Therapeutics’ record therefore sets out the transaction quantity, the per-share award price and the post-transaction holding.
FAQs
Q: What did Whitehawk Therapeutics award Bryan Ball?
A: Whitehawk Therapeutics awarded Bryan Ball 183,266 derivative securities through two transactions. The filing states the securities were awarded at $0 per share.
Q: How many derivative securities did Bryan Ball own afterward?
A: After the two transactions, Bryan Ball’s reported holding was 91,633 derivative securities. This figure is the post-transaction ownership reported in the filing.
Q: When were the Whitehawk Therapeutics transactions recorded?
A: Both Whitehawk Therapeutics derivative-security transactions were recorded on 15 September 2026. The transactions were recorded under code A, which identifies an award or grant.
Download Free Report – Explore 3 Stock Ideas & Industry Insights
Unlock 3 stock ideas and key industry insights in our free report. This information is general in nature and does not consider your personal objectives, financial situation, or needs. It is not financial advice.
All investments involve risk—consider independent advice before making any investment decisions.
View 3 Research Reports
Disclaimer:
Kalkine Equities LLC, with Delaware File Number 4697384, Foreign Qualification Registration in California File Number 202109211078, and Texas File Number 805521396, is authorized to provide general advice only. The information on https://kalkine.com/ does not take into account any of your investment objectives, financial situation or needs. You should consider the appropriateness of advice taking into account your own objectives, financial situation and needs and seek independent financial advice before making any financial decisions. The link to our Terms and Conditions and Privacy Policy has been provided for your reference. On the date of publishing the reports (mentioned on the website), employees and/or associates of Kalkine do not hold positions in any of the stocks covered on the website. These stocks can change any time and readers of the reports should not consider these stocks as advice or recommendations later.